Time to do NGS on all cancers, and study every cancer molecularly/genetically – Sucharu Prakash
It is time! Time to do NGS on all cancers, and study every cancer molecularly/genetically. Today, with NGS technology available, there’s no reason why any patient with cancer should miss out on a targeted therapy or clinical trial. National guidelines lag way behind in this rapidly advancing precision oncology field. Testing rates nationally are abysmal. But we can change this! I have led efforts at Texas oncology to ensure that every advanced solid tumor be tested with NGS, and this initiative has been a great success. This proves that such testing can be done on a large scale in the community. Moreover, legislators have listened – TX biomarker bill, just passed, will mandate coverage of such testing. If we don’t check, we don’t know…and the patients miss out! So, let’s make NGS testing of cancers a priority and a reality.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023